Breathe Well Live Well
|
Array Shares Climb After Asthma Drug Shows Positive Phase 2 Results
Xconomy Array hopes ARRY-502 can become the next successful oral treatment for asthma, CEO Ron Squarer said during a conference call about the results. The market is substantial, and it has been 15 years since the FDA last approved an oral non-steroidal drug … |
View full post on asthma – Google News
|
Shares jump as Array BioPharma reports positive results for asthma drug
The Pharma Letter US biotech firm Array BioPharma (Nasdaq: ARRY) saw its shares jump as it announced that its drug candidate for mild to moderate persistent allergic asthma, ARRY-502, an oral CRTh2 antagonist, met all primary and secondary endpoints. The company said … |
View full post on asthma – Google News
|
Treatment for Adults with Asthma Yield Positive Results
WBBJ-TV Many West Tennesseans who suffer from asthma are getting some relief thanks to a new procedure, called bronchial thermoplatsy. The non-drug procedure that can reduce severe asthma symptoms for people 18 and older. Doctors hope this treatment can … |
View full post on asthma – Google News
|
Boehringer Ingelheim presents positive efficacy data for tiotropium in asthma …
The Pharma Letter German family-owned drug major Boehringer Ingelheim presented a new subset of data from the Phase III UniTinA-asthma program relating to its already-marketed drug Spiriva (tiotropium) at the 2013 American Academy of Allergy, Asthma & Immunology … Boehringer Ingelheim drug shows benefits in new asthma trial |
View full post on asthma – Google News
|
Aerocrine: Positive reimbursement coverage continues for Aerocrine's asthma test
The Herald | HeraldOnline.com Specifically, FeNO testing is covered for the treatment of asthma when it is used in the diagnosis of allergic airway inflammation or when used in determining likelihood of steroid responsiveness in individuals with chronic symptoms suggestive of … |
View full post on asthma – Google News
|
Positive Data on MediciNova's MN-221 – Analyst Blog
NASDAQ MediciNova is developing MN-221, a highly selective beta(2)-adrenergic receptor agonist, for the treatment of acute exacerbations of asthma and COPD. In 2004, MediciNova licensed exclusive rights to MN-221 from Kissei Pharmaceutical Co., Ltd. in all … Drug trial signals hope for asthma sufferers MediciNova Announces Positive Preliminary Results From a Multi-Day, Repeat … Illinois Investor Commits to Buy MediciNova Stock |
View full post on asthma – Google News
|
MediciNova Announces Positive Preliminary Results From a Multi-Day, Repeat …
NASDAQ "There is a significant unmet medical need for an IV agent like MN-221 for asthma and COPD patients who are admitted to the ER due to a severe episode that is unresponsive to standard therapy," said Kazuko Matsuda, M.D., Ph.D., M.P.H, Chief Medical … |
View full post on asthma – Google News
 Medical Daily |
Report on Health of U.S. Kids' is Mostly Positive: Obesity and Asthma Still a …
Medical Daily A new report on the health of U.S. children is generally positive. Infant deaths, preterm births, abuse, violent crime and teen births have all decreased. Unfortunately more kids are living in poverty while asthma and obesity rates have increased. Annual Report on US Kids' Health a Mixed Bag Preterm Birth Rates and Infant Death Rates Drop |
View full post on asthma – Google News
 Daily Mail |
Positive Results in Trial for New Asthma Treatment
news Stories Synairgen, a drug development company that spun out of the University of Southampton, United Kingdom, has announced positive results of a phase 2 clinical trial of its asthma drug SNG001. The trial investigated the potential for SNG001 to protect … Positive SNG001 Phase II Asthma Clinical Trial Data Asthma drug 'protects sufferers from life-threatening symptoms caused by … Synairgen's 'breakthrough' asthma drug shines in Phase II trial |
View full post on asthma – Google News
Daily Mail |
Positive SNG001 Phase II Asthma Clinical Trial Data
Science 2.0 (press release) This pioneering trial investigated the potential for SNG001 (inhaled interferon beta) to protect asthmatics from respiratory virus infections (principally the common cold) that can spread to the lung, which are a major cause of worsening asthma … Asthma drug 'protects sufferers from life-threatening symptoms caused by … Synairgen's 'breakthrough' asthma drug shines in Phase II trial New drug 'reduces asthma symptoms' |
View full post on asthma – Google News